Triclabendazole
- TRADE NAME: Egaten (Novartis)
- INDICATIONS: Indicated for the treatment of fascioliasis in patients 6 years of age and older.
- SYNONYM: Egaten
- CLASS: Anthelmintic
- HALF-LIFE: 8 hours
FDA APPROVAL DATE: 02/13/2019
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:PREGNANCY CATEGORY: N/A
There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
QT Prolongation: May prolong QT interval. Monitor ECG in patients with a history of QT prolongation or who are taking medications which prolong the QT interval.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric